184 related articles for article (PubMed ID: 37754516)
1. An Overview of CD133 as a Functional Unit of Prognosis and Treatment Resistance in Glioblastoma.
Joyce T; Jagasia S; Tasci E; Camphausen K; Krauze AV
Curr Oncol; 2023 Sep; 30(9):8278-8293. PubMed ID: 37754516
[TBL] [Abstract][Full Text] [Related]
2. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
3. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A
J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659
[TBL] [Abstract][Full Text] [Related]
5. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
[TBL] [Abstract][Full Text] [Related]
6. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.
Brown DV; Filiz G; Daniel PM; Hollande F; Dworkin S; Amiridis S; Kountouri N; Ng W; Morokoff AP; Mantamadiotis T
PLoS One; 2017; 12(2):e0172791. PubMed ID: 28241049
[TBL] [Abstract][Full Text] [Related]
8. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.
Yang YP; Chang YL; Huang PI; Chiou GY; Tseng LM; Chiou SH; Chen MH; Chen MT; Shih YH; Chang CH; Hsu CC; Ma HI; Wang CT; Tsai LL; Yu CC; Chang CJ
J Cell Physiol; 2012 Mar; 227(3):976-93. PubMed ID: 21503893
[TBL] [Abstract][Full Text] [Related]
10. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
11. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
Jamal M; Rath BH; Tsang PS; Camphausen K; Tofilon PJ
Neoplasia; 2012 Feb; 14(2):150-8. PubMed ID: 22431923
[TBL] [Abstract][Full Text] [Related]
12. Matrix Hyaluronic Acid and Hypoxia Influence a CD133
Chen JE; Leary S; Barnhouse V; Sarkaria JN; Harley BAC
Tissue Eng Part A; 2022 Apr; 28(7-8):330-340. PubMed ID: 34435883
[TBL] [Abstract][Full Text] [Related]
13. Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays.
Nie S; Gurrea M; Zhu J; Thakolwiboon S; Heth JA; Muraszko KM; Fan X; Lubman DM
J Proteome Res; 2015 Feb; 14(2):814-22. PubMed ID: 25469866
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
15. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
16. A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling.
Yang F; Nam S; Brown CE; Zhao R; Starr R; Ma Y; Xie J; Horne DA; Malkas LH; Jove R; Hickey RJ
PLoS One; 2014; 9(4):e94443. PubMed ID: 24732116
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.
Yang YP; Chien Y; Chiou GY; Cherng JY; Wang ML; Lo WL; Chang YL; Huang PI; Chen YW; Shih YH; Chen MT; Chiou SH
Biomaterials; 2012 Feb; 33(5):1462-76. PubMed ID: 22098779
[TBL] [Abstract][Full Text] [Related]
18. Could We Address the Interplay Between CD133, Wnt/β-Catenin, and TERT Signaling Pathways as a Potential Target for Glioblastoma Therapy?
Behrooz AB; Syahir A
Front Oncol; 2021; 11():642719. PubMed ID: 33869033
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous phenotype of human glioblastoma: in vitro study.
Denysenko T; Gennero L; Juenemann C; Morra I; Masperi P; Ceroni V; Pragliola A; Ponzetto A; Melcarne A
Cell Biochem Funct; 2014 Mar; 32(2):164-76. PubMed ID: 23836332
[TBL] [Abstract][Full Text] [Related]
20. Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
Liu YC; Lee IC; Chen PY
J Neurooncol; 2018 May; 137(3):511-522. PubMed ID: 29357090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
